INTRODUCTION:

Middle Eastern respiratory syndromes reportedly a novel corona virus discovered in a Saudi Arabian exposed in June 2012. With several outbreaks documented on or epidemiology connected to the Arabian Peninsula, it has been connected to that region. the Saudi authorities documented 587 intense overall as of April 18, 2016 and 587 of those cases resulted in death. the virus is a major cause of public concern since it has a high fatality rate and no effective antiviral medication or vaccination. In ciliated human embryonal tracheal cells, covirus was first grown in 1965.^1,2,3

It is currently unknown how MERS-CoV evolved although it is a family C beta coronavirus having a unique genotype highly similar with other bats corona viruses of the identical clan, such as BtCoV-HKU4 and BtCoV-HKU5.⁴ MERS-CoV epidemics, coronavirus interest resurfaced as a trending subject. The family of positive standard RNA enclosed virus known as coronavirus is a suborder of Nidovirales phylum.⁵ The majority of confirmed coronaviruses infect and spread mostly among bats among mammals. Since 2012, a severe epidemic report of respiratory sickness from the Middle East (MERS) is being observed in the area known as the island peninsula of Arabia, most notably in the Korean Republic, increasing worries about possible improvement in the method of MERS coronavirus (CoV) spreading.^6,7,8 The most recent WHO statics indicate that there are 27 countries worldwide with 2494 laboratory- confirmed reported cases.⁹ The well-known host of this virus continues to be dromedary camels.^10,11 Many pieces of proof indicate to the possibility of MERS CoV propagation in camels that are dromedary, individuals.^12,13

Origin of Mres- CoV:

The separation of C beta -coronaviruses from other genetic origins on phylogenetic analysis supports the theory MERS-CoV was discovered in bats. In the year 2009 and 2011, a sizeable screening research of bats was carried out, with 4758 bats from Ghana representing 10 distinct kinds and 272 pipistrellus bats across 4 European countries.^14,15,16 The MERS-CoV is a new coronavirus as well as the initial one identified human ancestor 2C betacoronavirus.¹⁷ In 2002, the severe acute respiratory syndrome coronavirus (SARS-CoV) was the first known anthropogenic coronavirus to circulate throughout the population of humans, sparking an epidemic that resulted in 8,401 confirmed cases and 801 fatalities globally.MERS-CoV,a very hazardous coronavirus that possibly emerged in bats, is the next known zoonotic transmission.^18,19 A Yemeni aircraft which consumed raw milk from camels developed MERS-CoV and reported the detection of Qatari MERS-CoV in milk by camels.^20,21

Human-human transmission:

There have been several clusters of MERS-CoV infections recorded mostly, among family members and health professionals, indicating that close contact is the most likely way to spread the disease. 24 healthcare workers in an Al Hasa healthcare facility, Republic of Saudi Arabia comprised biggest collection to date, while three afflicted brothers from Riyadh, KSA, comprised largest family cluster.^22,23

Camel to Human:

MERS-CoV, SARS-CoV, and SARS-CoV-2 are all initially transmitted via mammals to humans. While bats are regarded to be prospective hosts for intermediate species, new study reveals that the dromedary camels constituted the key route of MERS-CoV spread.²⁴

Drug targets of MERS-CoV:

MERS-CoV, like numerous additional corona viruses, comprises of four unique protein structures: spike (S) proteins, envelope (E), membrane (M), and nucleocapsid (N). Additionally, MERS-CoV contains two large polyproteins that are known as pp1a and pp1ab, which work in tandem with proteins that are seen in numerous corona viruses. The constituents of MERS-CoV's structural and non-structured proteins were utilised as targets for therapy when paired.²⁵

1. Lopinavir:

The therapy of COVID-19 induced by SARS-CoV-2, lopinavir and ritonavir were previously being studied.⁴¹

MOA: The HIV lifecycle consists of three distinct stages: assembly, during which vital viral components are created and packaged; budding, during Throughout maturity, the particle of viruses changes shape and becoming infectious after crossing the host cell's plasma membrane is dividing and producing a lipid coating..The Gag polyprotein, together alongside the byproducts of the breakdown of proteins, integrates many phases and serves as the virus's major architectural protein. It is crucial to the virus's lifecycle. The Gag polyprotein is cleaved by HIV-1 protease, a dimeric aspartic protease that is required for several phases throughout the HIV virus transmission.²⁶ The medicine lopinavir inhibits the HIV-1 protease enzyme. The layout within molecule depends upon the "peptidomimetic" idea; it contains a hydroxy ethylene framework that looks like a typical peptide bond (cleaved by HIV protease) however is unable to be broken. Lopinavir promotes the formation of immature, not contagious virus particles by suppressing HIV-1 activity of protease and, as a result, the breakdown of proteins involving the Gag polyprotein.^27,28

Uses: Lopinavir and ritonavir are employed in conjunction with additional products medications to treat the effects of HIV getting infected. Lopinavir and ritonavir are two examples of inhibitors of protease. They work by reducing the amount of HIV in bloodstreams.

2. Acyclovir:

A medication known as an antiviral nucleotide analogue can be used to treat acute herpetic keratitis, varicella zoster, viral labialis, and herpes labialis. It is often used as the initial choice of treatment for these infectious agents, and specific medications are suggested for children who are under six years age.

MOA: Acyclovir is converted to zovirax monophosphate by viral thymidine kinase, then to acyclovir diphosphate by guanylate kinase. Acyclovir triphosphate is converted to acyclovir by various enzymes.It integrates into DNA, attracting viral DNA polymerase more than cellular DNA polymerase. Acyclovir triphosphate outcompetes viral DNA polymerase, rendering it inactive and preventing subsequent bases from joining.^29,30,31

Uses: Acyclovir is a medication utilised for managing the symptoms of infantile viral illnesses, influenza, shingles, viral infections of the lips and mouth, skin, brain, and mucous membranes. Additionally, recurring genital herpes virus infections are treated with acyclovir.

3. Ribavirin:

Ribavirin is a synthetic guanosine nucleoside that functions as a medicinal product with broad-spectrum effectiveness against a number of RNA and DNA viruses by inhibiting viral mRNA transcription. It is mainly used to treat hemorrhagic fever caused by viruses and hepatitis C.

MOA: Ribavirin inhibits viral RNA and protein production through various mechanisms. It converts to monophosphate, diphosphate, and triphosphate metabolites, inhibiting viral mRNA polymerase and preventing the formation of defective virions. Ribavirin also prevents the host's GTP pool from being depleted and inhibits inosine monophosphate dehydrogenase (IMPDH). It induces the target virus to change more frequently, resulting in an "error catastrophic." Ribavirin blocks HCV RNA elongation and boosts mutagenesis. It favors a Th1 phenotype over a Th2 response, modulating the host's immune response. Ribavirin inhibits the expression of genes linked to apoptosis, hepatic stellate cell activation, and interferon suppression in vitro while increasing the induction of interferon-related genes. Ribavirin inhibits the expression of genes linked to apoptosis, hepatic stellate cell activation, and interferon suppression in vitro while increasing the induction of interferon-related genes.^32,33

Uses: Ribavirin may be used to treat intentionally transmitted viral haemorrhagic fever in the case of biological warfare. Additionally, ribavirin is occasionally used to treat SARS, a virus that can result in breathing difficulties, pneumonia, and even death.

4. Chloroquine:

On June 15, 2020, the FDA removed the authorisation for hydroxychloroquine and chloroquine to be used as an emergency therapy for COVID-19.³⁴

MOA: Chloroquine inhibits heme to hemozoin transformation in malarial trophozoites by inhibiting heme polymerase enzyme activity. This destroys the parasite when harmful hemelevels in Plasmodium species grow. Chloroquine diffuses across cell membranes in endosomes, lysosomes, and Golgi vesicles, raising pH and preventing virus particles from cell fusion and entrance. It does not affect ACE2 expression on cell exteriors but impedes terminal glycosylation of ACE2, preventing virus entry.^38,39,40

Uses: Chloroquine is employed to avoid as well as cure malaria. It additionally serves for the treatment of extra intestinal amebiasis, a liver disease that results from protozoa. In certain hospitalised individuals, chloroquine may be employed as well for the treatment of COVID-19 coronavirus.General safety precautions, such routinely washing their hands before and after coming into touch with the animals, should be taken by visitors to farms, marketplaces, barns, and other sites housing dromedary camels and other animals.

Prevention: A general safety precaution to follow when visiting barns, markets, farms, and other areas with dromedary camels and other animals is to wash your hands before and after touching any of the animals.Meat and dairy products from undercooked animals are more susceptible to infection from a wide range of viruses that can infect people and cause sickness.So,those who are more likely to suffer a serious illness should refrain from handling dromedary camels, consuming uncooked meat, or consuming camel milk or urine.

REFERENCES:

1. Zaki AM, Boheemena S, Bestebroer TIM, Osterhaus A, Fouchier R. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012; 367: 1814–20. doi:10.1056/NEJMoa1211721.

2. Command and Control Center (CCC) Statistics – April 2016.Ministry of Health (MOH) – Kingdom of Saudi Arabia. http://www.moh.gov.sa/en/CCC/ PressReleases/Pages/default.aspx. Accessed 15 Apr 2016.

3. Tyrel DA, Bynoe ML. Cultivation of a novel type of common cold virus in organ culture. Br Med J. 1965; 1(5448): 1467–70

4. Boheemena S, Graafa M, Lauberb C, Bestebroera TM, Raja S, Zaki AM, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio. 3(6): doi: 10.1128/mBio.00473-12.

5. Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev. 2015; 28: 465–522. doi:10.1128/CMR.00102-14.

6. A. M. Zaki, S. van Boheemen, T. M. Bestebroer, A. D. Osterhaus, R. A. Fouchier, N. Engl. J. Med. 2012; 367: 1814 – 1820.

7. A. Bermingham et al., Euro Surveill. 2012; 17: 20290.

8. World Health Organization, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) (2015); www.who.int/emergencies/ mers-cov/en/.

9. Hemida MG, Elmoslemany A, Al-Hizab F, Alnaeem A, Almathen F, Faye B, Chu DK, Perera RA, Peiris M. Dromedary camels and the transmission of Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Transbound Emerg Dis. 2017; 64(2): 344–353

10. Adney DR, Bielefeldt-Ohmann H, Hartwig AE, Bowen RA. Infection, replication, and transmission of Middle East respiratory syndrome coronavirus in alpacas. Emerging Infect Dis. 2016; 22(6): 1031–1037.

11. Adney DR, Letko M, Ragan IK, Scott D, van Doremalen N, Bowen RA, Munster VJ. Bactrian camels shed large quantities of Middle East respiratory syndrome coronavirus (MERS-CoV) after experimental infection. Emerg Microbes Infect. 2019; 8(1): 717–723.

12. Azhar EI, El-Kafrawy SA, Farraj SA, Hassan AM, Al-Saeed MS, Hashem AM, Madani TA. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med. 2014; 370(26): 2499–2505.

13. Azhar EI, Hashem AM, El-Kafrawy SA, Sohrab SS, Aburizaiza AS, Farraj SA, Hassan AM, Al-Saeed MS, Jamjoom GA, Madani TA. Detection of the Middle East respiratory syndrome coronavirus genome in an air sample originating from a camel barn owned by an infected patient. MBio. 2014; 5(4): e01450–e01414.

14. De Benedictis P, Marciano S, Scaravelli D, Priori P, Zecchin B, Capua I, et al. Al-pha and lineage C betaCoV infections in Italian bats. Virus Genes. 2014; 48: 366–71. doi:10.1007/s11262-013-1008-x.

15. Wacharapluesadee S, Sintunawa C, Kaewpom T, Khongnomnan K, Olival KJ, Epstein JH, et al. Group C betacorona-virus in bat guano fertilizer, Thailand. Emerg Infect Dis. 2013; 19: 1349–51. doi:10.3201/eid1908.130119.

16. Annan A, Baldwin HJ, Corman VM, Klose SM, Owusu M, Nkrumah EE, et al. Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe. Emerg Infect Dis. 2013; 19: 456. doi:10.3201/eid1903.121503.

17. Raj VS, Osterhaus AD, Fouchier RA, Haagmans BL. MERS: Emergence of a novel human coronavirus. Curr Opin Virol 2014; 5: 58–62. doi: 10.1016/j.coviro.2014.01.010

18. World Health Organization. Consensus document on the epidemiology ofsevere acute respiratory syndrome (SARS). 2003. Available: http://www.who.int/csr/sars/en/WHOconsensus.pdf. Accessed 29 June 2014.

19. van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, et al. Genomic characterization of a newly discovered coronavirus associated withacute respiratory distress syndrome in humans. MBio. 2012; 3: e00473–12.doi:10.1128/mBio.00473-12.

20. World Health Organization (2014) Global Alert and Response: Middle East respiratory syndrome coronavirus (MERS-CoV) – update, 07 May 2014.Available: http://www.who.int/csr/don/ 2014_05_07_mers_yemen/en/. Ac-cessed 30 Aug 2014.

21. Reusken C, Farag E, Jonges M, Godeke G, El-Sayed A, et al. Middle east respiratory syndrome coronavirus (MERS-CoV) RNA and neutralising anti-bodies in milk collected according to local customs from dromedary camels, Qatar. April 2014. Euro Surveill 19: p20829ii. Available: http:// www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20829. Accessed 6 November 2014.

22. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, et al. Hospital outbreak of middle east respiratory syndrome coronavirus. N Engl J Med. 2013; 369: 407–416. doi:10.1056/ NEJMoa1306742

23. Breban R, Riou J, Fontanet A. Interhuman transmissibility of middle east respiratory syndrome coronavirus: Estimation of pandemic risk. Lancet. 2013; 382: 694–699. doi:10.1016/S0140-6736(13)61492-0

24. Raj VS, Osterhaus AD, Fouchier RA, Haagmans BL MERS: Emergence of a novel human coronavirus. Curr Opin Virol. 2014; 5: 58-62.

25. Mustafa, S., Balkhy, H., and Gabere, M. N. Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review. Journal of Infection and Public Health. 2018; 11(1): 9-17. doi: 10.1016/j.jiph.2017.08.009.

26. Sundquist WI, Krausslich HG. HIV-1 assembly, budding, and maturation. Cold Spring Harb Perspect Med. 2012 Jul; 2(7): a006924. doi: 10.1101/cshperspect. a006924

27. FDA Approved Drug Products: Kaletra (lopinavir/ritonavir) for oral use

28. De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009 Apr; 33(4): 307-20. doi: 10.1016/j.ijantimicag.2008.10.010. Epub 2008 Dec 23.

29. King DH. History, pharmacokinetics, and pharmacology of acyclovir. J Am Acad Dermatol. 1988 Jan; 18(1 Pt 2): 176-9. doi: 10.1016/s0190-9622(88)70022-5.

30. O'Brien JJ, Campoli-Richards DM. Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1989 Mar; 37(3): 233-309.

31. Miller WH, Miller RL. Phosphorylation of acyclovir diphosphate by cellular enzymes. Biochem Pharmacol. 1982 Dec 1; 31(23): 3879-84. doi: 10.1016/0006-2952(82)90305-7.

32. Martin P, Jensen DM. Ribavirin in the treatment of chronic hepatitis C. J Gastroenterol Hepatol. 2008 Jun; 23(6): 844-55. doi: 10.1111/j.1440-1746.2008.05398. x.

33. Te HS, Randall G, Jensen DM. Mechanism of action of ribavirin in the treatment of chronic hepatitis C. Gastroenterol Hepatol (N Y). 2007 Mar; 3(3): 218-25.

34. FDA. Emergency use Authorization for Hydroxychloroquine and Chloroquine Revoked

35. Coronado LM, Nadovich CT, Spadafora C. Malarial hemozoin: from target to tool. Biochim Biophys Acta. 2014 Jun; 1840(6): 2032-41. doi: 10.1016/j.bbagen.2014.02.009. Epub 2014 Feb 17.

36. Chou AC, Fitch CD. Heme polymerase: modulation by chloroquine treatment of a rodent malaria. Life Sci. 1992;51(26):2073-8. doi: 10.1016/0024-3205(92)90158-l

37. Slater AF, Cerami A. Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites. Nature. 1992 Jan 9; 355(6356): 167-9. doi: 10.1038/355167a0.

38. Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet. 1996 Oct; 31(4): 257-74. doi: 10.2165/00003088-199631040-00003.

39. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res., 2020 Mar; 30(3): 269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.

40. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005 Aug 22; 2: 69. doi: 10.1186/1743-422X-2-69.

41. Nature Biotechnology. Coronavirus puts drug repurposing on the fast track.

Received on 19.03.2024 Revised on 30.05.2024

Accepted on 06.07.2024 Published on 07.12.2024

Available online on December 30, 2024

Res.J. Pharmacology and Pharmacodynamics.2024;16(4):297-300.

DOI: 10.52711/2321-5836.2024.00051

A Review on MERS-CoV, The Coronavirus Linked to Middle Eastern Respiratory illness